Genextra S.p.A. 13D and 13G filings for Quince Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-18 1:46 pm Purchase | 2024-10-18 | 13G | Quince Therapeutics, Inc. QNCX | Genextra S.p.A. | 2,806,611 6.490% | 280,661 (+11.11%) | Filing |
| 2023-12-14 5:51 pm Purchase | 2023-10-20 | 13G | Quince Therapeutics, Inc. QNCX | Genextra S.p.A. | 2,525,950 5.890% | 2,525,950 (New Position) | Filing |